Name: The Story of Glp-1: A Historical Journey in the Treatment of Diabetes and Obesity (en Inglés)
SKU: 66285440
Price: 2963.26 MXN
Availability: InStock
Author: Holst, Jens Juul
ISBN: 9780443332876

portada The Story of Glp-1: A Historical Journey in the Treatment of Diabetes and Obesity (en Inglés)

The Story of Glp-1: A Historical Journey in the Treatment of Diabetes and Obesity (en Inglés)

Formato

Libro Físico

Editorial

Academic Press

Autor

Holst, Jens Juul

Idioma

Inglés

N° páginas

188

Encuadernación

Tapa Dura

ISBN13

9780443332876

The Story of Glp-1: A Historical Journey in the Treatment of Diabetes and Obesity (en Inglés)

Holst, Jens Juul (Autor) · Academic Press · Tapa Dura

Libro Nuevo Importado

Envío: 19 a 25 días háb.

$ 5,387.75$ 2,963.26

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 2,963.26

¡Envío Gratis! Llega entre el 13 Oct y el 22 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "The Story of Glp-1: A Historical Journey in the Treatment of Diabetes and Obesity (en Inglés)"

The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide. The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.